![Karl D. Handelsman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karl D. Handelsman
Fondatore presso Codon Capital
Profilo
Karl D.
Handelsman is the founder of Codon Innovation LLC, which was founded in 2013.
He is currently working as an Investment Director at Roche Ventures since 2017.
Additionally, he holds director positions at Good Therapeutics, Inc. and Bonum Therapeutics, Inc. Mr. Handelsman has previously worked as a Director of Business Development at Millennium Pharmaceuticals, Inc. from 1996 to 1997.
He also served as an Independent Director at Tetraphase Pharmaceuticals, Inc. in 2013.
From 1999 to 2013, he was a Managing Director at Presidio Partners.
Mr. Handelsman has held director positions at Neos Therapeutics, Inc., Intellikine LLC, Velocity Pharmaceutical Development LLC, Tularik, Inc., and Whitehead Institute for Biomedical Research.
He completed his graduate degree at Harvard University, undergraduate degree at Boston University, and obtained an MBA from Massachusetts Institute of Technology.
Posizioni attive di Karl D. Handelsman
Società | Posizione | Inizio |
---|---|---|
Roche Ventures
![]() Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Investitore di Private Equity | 01/01/2017 |
Good Therapeutics, Inc.
![]() Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Direttore/Membro del Consiglio | - |
Bonum Therapeutics, Inc.
![]() Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Codon Capital | Fondatore | 01/01/2013 |
Precedenti posizioni note di Karl D. Handelsman
Società | Posizione | Fine |
---|---|---|
TETRAPHASE PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 01/03/2013 |
Presidio Partners
![]() Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Investitore di Private Equity | 01/01/2013 |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1997 |
Velocity Pharmaceutical Development LLC
![]() Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | - |
NEOS THERAPEUTICS, INC. | Direttore/Membro del Consiglio | - |
Formazione di Karl D. Handelsman
Harvard University | Graduate Degree |
Boston University | Undergraduate Degree |
Massachusetts Institute of Technology | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 12 |
---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Tularik, Inc.
![]() Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Tetraphase Pharmaceuticals, Inc.
![]() Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Presidio Partners
![]() Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Finance |
Whitehead Institute for Biomedical Research
![]() Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Commercial Services |
Neos Therapeutics, Inc.
![]() Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
Roche Ventures
![]() Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | Finance |
Intellikine LLC
![]() Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
Velocity Pharmaceutical Development LLC
![]() Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Retail Trade |
Good Therapeutics, Inc.
![]() Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Health Technology |
Codon Capital | Finance |
Bonum Therapeutics, Inc.
![]() Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Karl D. Handelsman